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ABSTRACT
STUDY ON THE HUMAN GUT BACTERIA UNDER DIFFERENT ECOLOGICAL
CONDITIONS : ANTIBIOTIC PERTURBATION AND DIETARY QUERCETIN
SHRUTI SHASHIDHARAN MENON
2021
The human intestine encompasses a vast community of microorganisms known as the
gut microbiota that play a crucial role in maintaining health. Common perturbations such
as changes in the normal diet, antibiotic treatment, and changes in environmental
conditions can alter the gut microbiome. This can create dysbiosis in the gut leading to
disease conditions. Therefore, it becomes important to determine the forces that influence
the gut microbial ecology. In the first study, we focus on antibiotic perturbations on
microbial succession and resilience in a synthetic consortium consisting of the most
prevalent gut bacteria in humans. In addition, we investigated the ability of the
consortium to provide colonization resistance against the gut enteric pathogen
Clostridium difficile. The results show that the 14-species synthetic community formed
after antibiotic perturbation is able to resist C. difficile, providing us insights for
understanding the community effect against the pathogen and the possibility of using the
synthetic community as a therapeutic. The bacteria Bacteroides caccae, Bacteroides
thetataimicron, and Parabacteroides distanosis appear to increase significantly after
antibiotic perturbation, accenting their role in inhibiting C. difficile growth. In the second
study, we focus on the effects of supplementing quercetin on the gut microbiome. By
using bioinformatic analysis, we predicted a subset of gut bacteria capable of degrading
the flavonoid quercetin. From this information, we propose a set of quercetin degraders in
the healthy individual that may be capable of producing antiproliferative metabolites

xi
through quercetin biotransformation. The bioinformatic analysis showed 64 gut bacteria
were predicted to have enzymes capable of degrading quercetin. The abundance of the 64
bacteria was determined by analyzing shotgun metagenomes public datasets of healthy
and colorectal cancer (CRC) patients and resulted in 11 bacteria being significantly
higher in the healthy population. The two studies lay the groundwork to study the gut
communities under different ecological conditions in further depth. Understanding the
niche an organism occupies in the gut, its survival strategies, the interactions with other
microbes and advantage of certain phenotypes of gut communities under stress can
provide the answer to the basic functioning of the human microbiota.

1
1. CHAPTER 1: POPULATION STRUCTURE, STABILITY, RESILIENCE AND
THE ROLE OF SYNTHETIC GUT MICROBIOTA IN COLONIZATION
RESISTANCE

1.1 Introduction
1.1.1

Core microbiota and its importance

The colon is densely populated with gut bacteria commonly known as “gut
microbiota,” and these bacteria play an important role in maintaining the integrity and
stability of the gut [1]. The dynamic and complex interactions between the gut microbiota
helps to maintain gut health. The complexity of the gut microbiota makes it challenging
to study the underlying ecological concepts and the metabolic interactions taking place.
The transient microorganisms add to the already existing complex community [2]. These
transient microbes fluctuate depend on the environment and diet. Even with advances in
sequencing technologies and culturing, a major portion of the community still remains
unknown or has not been cultivated. Thus, along with mining for the microbes associated
with human gut, there have been efforts to study the core microbiota [3, 4]. The core
microbiota are the permanent and stable members of the gut community. The core
microbiome can be defined as the set of bacteria that are conserved among individuals
and are essential for better functioning of the human gut [5].Therefore, these core
bacteria are the most prevalent or shared across the human gut.
1.1.2

Importance of studying synthetic microbial communities

It is difficult to carry out ecological studies in complex gut microbial systems;
therefore, synthetic microbial communities are better suited for system-level studies [6].
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The synthetic communities formed should be able to retain the key features of the natural
environment [7]. Famous examples of synthetic communities are the Schaedler flora by
Rusell W. Schaedler and the Altered Schaedler flora (ASF) developed by R.P. Orcutt, a
model community of eight microorganisms [8, 9]. The synthetic microbial consortia
helps to understand how the community dynamics shape the microbe-microbe
interactions in the gut [10]. Thus, these communities are used as model systems to
understand and study the functional, ecological and structural roles of microbiota. Such
synthetic communities can be studied using in vitro models such as batch-culture, batch
fermentation, and continuous flow, or in vivo models such as germ-free mice [11, 12]. In
vitro models with defined gut communities provide controlled systems to study
ecological interactions as they eliminate the multiple host-related factors influencing
microbial interactions [10, 13, 14]. Also, studies have used several defined synthetic
microbial communities developed from human gut microbiota to understand specific
interaction patterns such as cross-feeding, syntropy and auxotrophy [10, 15].
Furthermore, using a top-down ecological perspective, we can study the overall function,
resistance and resilience of the synthetic microbial communities [7]. Bottom-up
ecological perspectives can be used to gain understanding in the interactions or relations
between microbes and build a community from these interactions [6, 7]. Therefore, the
ecological mechanistic understanding of the human gut system can be well documented
using cultured synthetic communities [6]. These experiments can be performed in in vitro
or in vivo systems driven by mathematics. In our study, we define a synthetic community
of 14 bacteria which are known to be among the top 20 most prevalent bacterial species
in the human gastrointestinal tract as identified by Forster et al. (2019) analyzing 13,490
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human gastrointestinal metagenomes [16]. These 14 gut species are proposed as a model
of core gut consortia for studying resistance against Clostridium difficile infections
(CDI). We use minibioreactor arrays (MBRA) to study the ecological succession of the
synthetic gut consortium and as a model for understanding CDI.
1.1.3

Importance of studying colonization resistance against enteric pathogens

The human gut plays an essential role in maintaining health. It therefore becomes
crucial to study how the microbial communities confer resistance against pathogens as
well as other perturbations such as antibiotics or a change in diet. Studies have shown
external perturbations, such as antibiotic use, can shift the gut composition and can lead
to changes in the integral human-microbe interactions needed for maintaining human
physiology [17-22]. The imbalance or change of microbiota caused in the gut is known as
dybiosis. Dysbiosis due to external perturbations in the gut can lead to disease-like
conditions, reducing colonization resistance. Therefore, it becomes crucial to understand
the key players involved in generating resistance against enteric pathogens. The next step
is to understand how this resistance is achieved by studying the microbial interacting
networks. These interactions can be in the form of ecological competition, production of
bacteriocins, or by modulating the immune system [23]. Next-generation sequencing and
metagenomics have opened new windows in the microbiome sciences. Most of the
studies have performed quantitative analysis such as diversity analysis or relative
abundances on composition of the microbial communities [24-26]. There have also been
in vivo studies using ecological models to study microbial dynamics between species in
the presence of perturbations such as antibiotics [23, 25, 27]. The goal of this study is to
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develop a model system useful for studying integral human-microbe interactions that are
required to resist enteric pathogens.

1.1.4

Choosing Clostridium difficile and antibiotic to study succession and
resistance

C. difficile is an enteric pathogen that is known to cause antibiotic-associated
diarrhea (AAD) or colitis [28] and is a major healthcare issue around the globe [29]. The
treatment for Clostridium difficile infection CDI is usually metronidazole and/or
vancomycin depending on the severity. However, 20% of patients develop recurrent CDI
[30]. Therefore, microbial-based therapeutics such as the fecal microbiota transplant
(FMT) and selected microbial mixes have emerged as treatment strategies [31-33].
However, there are concerns of infection from the donor fecal sample during FMT; thus,
the use of a microbial mix as a therapeutic is being studied as substitute for stool
transplant [33]. The number of bacteria in the defined mixtures used in studies to reduce
or resolve CDI varies from 10 to 33 [32, 33]. Another study showed effect of defined
bacterial mixtures in mice [34]. Also, there are well developed in vitro systems used to
study C. difficile physiology [35]. Our study uses C. difficile and the antibiotic
clindamycin, which is a third-generation cephalosporin and aminopenicillin associated
with C. difficile infection CDI [36, 37].
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1.1.4.1 Formulating the synthetic blend
Our hypothesis is the dominant or core members of the bacteria are important for
conferring resistance against the CDI. The synthetic consortium was formulated based on
a study that performed bioinformatic analysis to find 20 most prevalent species from
13,490 human gastrointestinal metagenomes [16]. Based on their study, our lab cultured
18 out of the 20 bacteria species from Prevotella-dominated human gut microbiota using
culturomics (Table 1.1). Out of the 18 species, Fecalibacterium praustaunzii,
Bifidobacterium adolescentis and Dorea longicatenum were excluded due to the pH of
medium was dropped below 5.6 after 24 h growth and low pH inhibits C. difficile growth.
Anaerostipes hadrus was eliminated due to issues related to culturing the species. The 14
species blend consists of both C. difficile inhibiting (high, low, moderate) and noninhibiting bacteria. Apart from the different C. difficile inhibition efficiency, the 14
species also had slow growers (48 h) and fast growers (24 h) in the mBHI. A previous
study on the substrate utilization ability of the individual bacteria also showed the
differences in the utilization of these bacteria [38]. Overall, this blend consists of bacteria
with different phenotypic characteristics which will help gain a better idea of the effect
on C. difficile as a microbial community. Preliminary work on phenotypic assays such as
the C. difficile inhibition assays, Volatile Fatty Acid (VFA) production, nutrient
utilization patterns have been done for the 14 bacterial monocultures [38]. Since the 20
species were termed to be the most prevalent in the metagenome samples, we termed the
blend as the “core synthetic consortium.”

6
Table. 1.1. The 14 species present in the Prevotella-dominated human gut microbiota.
Phylum

Family

Bacteroidaceae
Bacteroidetes
Actinobacteria

Porphyromonadaceae
Bifidobacteriaceae
Coriobacteriaceae
Lachnospiraceae

Firmicutes
Proteobacteria

1.1.5

Enterobacteriaceae

Species

Bacteroides caccae
Bacteroides dorei
Bacteroides ovatus
Bacteroides thetaiotaomivron
Bacteroides uniformis
Bacteroides vulgatus
Parabacteroides distasonis
Parabacteroides merdae
Bifidobacterium longum
Collinsella aerofaciens
Blautia obeum
Fusicatenibacter saccharivorans
Roseburia faecis
Escherichia coli

Importance of this study

This study will help us understand the ecological events occurring after
perturbations and define whether the prevalent or dominant species are the keystone
players involved in conferring colonization resistance against CDI. This will present a
synthetic blend not only as a bacteriotherapy but also provide a model consortium to
understand the integral microbe-microbe and host-microbe interactions crucial for
resisting C. difficile and the possibility of recovering healthy gut post-CDI.
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1.1.6

Objectives of this study

We aim to infer ecological “core synthetic community” dynamics under
perturbations using microbiological techniques, bioinformatic analysis and mathematical
modeling with the following objectives:
1. Determine the population structure and the ecological succession of core synthetic gut
microbiota.
2. Determine the stability of core synthetic gut microbiota following antibiotic treatment
and C. difficile invasion.
3. Determine the resilience of core synthetic gut microbiota following antibiotic treatment
and C. difficile invasion.
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1.2 Methodology
1.2.1

Abundance mapping on the public dataset

The bacterial abundance was mapped in order to understand the trend of the 14
species in the human gut during healthy conditions, after antibiotic perturbation and CDI.
Public shotgun metagenome reads were downloaded from the study (Milani et al.) which
consisted of 30 CDI-negative subjects not on antibiotic treatment (AB− group), 29 CDInegative exposed to antibiotic treatment (AB+ group) and 25 CDI-positive (CDI group)
[39]. The shotgun reads were converted to FASTQ format using sratoolkit [40]. Further,
the raw reads were processed for quality control and to remove host reads using
metawrap- readqc module [41]. Kaiju software for mapping and taxonomic classification
using a custom database of the 14 bacterial protein sequences [42]. The custom database
was created and indexed using the annotated protein files from the 14 bacterial whole
genomes. These annotated protein sequences were generated using prokka from the
assembled whole-genome sequences and the headers for each protein file were formatted
to NCBI taxon identifier of each species using AWK command [43]. The kaiju2table (-r
species) command was for generating .tsv format file containing abundance data and the
abundance map was generated using R ggplot package [44].
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1.2.2

General Workflow

Fig. 1.1. demonstrates the experimental timeline for the sampling scheme during
the minibioreactor continuous flow assay. For the culturing of the bacterial isolates and
minibioreactor experiment, we used the modified brain heart infusion (mBHI) media
(Table 1.2). The bacterial cultures, each at 0.5 optical density (O.D.)600 nm, were mixed
equally (Mix 14) and 300 µl inoculated in each group (6 wells/ group) and allowed to
stabilize for 7 days. This timeline was decided from a study that showed fecal community
being stabilized after one week (~21 turnovers) [45]. The three groups included one
control group which contained Mix 14 until day 23. The second group contained Mix 14
with antibiotic perturbation at day 8 and addition of C. difficile at day 20, which is the
antibiotic treatment group. The third group contained Mix 14 with antibiotic perturbation
at day 8 and addition of C. difficile at day 13; the CDI group. On day 8, antibiotic
clindamycin was added to antibiotic and CDI treatment group s. The antibiotic treatment
continued for four days and stopped on day 12. The C. difficile was inoculated on day 13
at 105 cells in CDI treatment group. For antibiotic treatment group, C. difficile was
inoculated on day 20 at 105 cells in antibiotic treatment group. After addition of C.
difficile in antibiotic treatment group and CDI treatment group, the CFU counts for C.
difficile were performed daily by the serial dilution method on Clostridium difficile
selective agar (CDSA) plates (Table 1.3).
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Fig. 1.1. Experimental timeline depicting the sampling scheme; the blue circles depict
sampling for growth measurements, VFA and 16S samples, the orange triangle depicts
the performance of the CLPP assay, and the pink triangle depicts CDSA plating. The
CDSA plating was performed from day 14 to 23.

Table. 1.2. The composition of mBHI media used for this study.
Composition
Ingredients
Brain heart infusion (BHI)
Inulin
Yeast extract
L-cysteine
Resuarine
Bovine bile
Hemin
Menadione
MES
10N NaOH

per liter
37 g
10 g
5g
0.3 g
1 ml
0.05 g
1 ml
1 ml
1 M stock (add 100 ml to 1 L)
Adjust pH to 6.8, and then bring up to 1 L
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Table. 1.3. The composition of CDSA media used for this study.
Composition
Ingredients

per liter

Clostridium difficile agar (CDSA)

69 g

D-Cycloserine
Cefoxitin

0.5 g (500mg/5 ml; add 5ml in 1L)
0.016 g (100mg/ml stock; add 160 µl in 1)

L-cysteine

0.3 g

Resuarine

1 ml/L (0.25 mg/ml)

1.2.3

Bacterial culture and storage

The 14 bacterial strains obtained from our culturomics collection of 102 human
gut libraries were cultured in an anaerobic chamber (Coy Lab). The cultures were grown
in 3ml mBHI at 37°C. The strains, Bacteroides caccae (SG-0247), Bacteroides dorei
(SG-1212), Bacteroides ovatus (SG-0349), Bacteroides thetaiotaomicron (SG-0363),
Bacteroides uniformis (SG-0817), Bacteroides vulgatus (SG-0619), Bifidobacterium
longum (SG-0552), Blautia obeum (SG-0764), Collinsela aerofaciens (SG-908),
Escherichia coli (SG-1357), Fusicatenibacter saccharivorans (SG-0858),
Parabacteroides distasonis (SG-0828), Parabacteroides merdae (SG-0560) and
Roseburia faecis (SG-0935), were stocked at 0.5 O.D600 in 10% DMSO (0.9ml culture +
0.1ml DMSO) and stored at -80°C until use. The samples were pooled (14 ml inoculum)
together in equal proportion prior to the MBRA inoculation. The vegetative cells of
Clostridium difficile strain R20291 was cultured in mBHI media, and a stock
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concentration of 105 cells was frozen in 10% DMSO (1.8 ml + 0.2 ml), and then stored at
-80°C.
1.2.4

In-vitro Bioreactor array

For the in vitro set-up, MBRAs were sterilized and assembled as described in the
MBRA manual [35]. For the experiment, three groups of the minibioreactor were set up
with the conditions as described. The input and output on the Watson Marlow pumps
were set at 1 rpm and 2 rpm respectively. The rotating magnetic stirrer was set at 130
rpm. The media was allowed to flow continuously (sterile run) for 24 hours in all three
group. 300 µl of the equally pooled samples was inoculated with a retention time of 16h.
The minibioreactors were operated for 23 days. Samples were collected from each reactor
well as per the experimental design (Fig. 1.1). The antibiotic dose was provided from
day 8 to day 12. 150 µl of 25 mg/ml clindamycin antibiotic was added to each reactor of
antibiotic treatment group and CDI treatment group on day 8. Each source bottle
connected to antibiotic treatment group and CDI treatment group had a final clindamycin
dose of 250ug/ml. On day 13, 150 µl of 104 C. difficile vegetative cells were added to
CDI treatment group after 24h replacement of antibiotic-containing source media. On day
20, 150 µl of 104 C. difficile vegetative cells were added to antibiotic treatment group to
check if the microbial community formed after 9 days of antibiotic treatment was able to
resist the pathogen.
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1.2.5

Growth measurements

Bacterial growth was determined using optical density measurements at 600 nm
(Eppendorf BioPhotometer), and the pH of the culture measured with a pH meter (Mettler
Toledo). The O.D. and pH values from day 2 to day 23 were plotted using Microsoft
Excel. 100 µl cultures obtained from the reactor wells were used for obtaining CFU
counts by the serial dilution method. The total CFU counts were obtained on days 8, 12
and 20 on mBHI plates. For the C. difficile CFU counts, the cultures from antibiotic and
CDI treatment groups were plated on CDSA plates.

1.2.6

16S amplicon sequencing

For the time-series change in the bacterial community, 500 µl of media sample
was taken from all three reactor groups from day 2 to day 23. Also, inoculum used on day
1was stored for DNA extraction. DNA from 397 samples was extracted using the
Powersoil DNA isolation kit (MoBio Laboratories Inc, CA). After extraction, the quality
of DNA was measured using NanoDrop™ one (Thermo Fisher Scientific, DE) and was
stored at −20°C until further use. Amplicon sequencing of the samples was performed
using Illumina MiSeq platform with paired-end V3 chemistry. The library was prepared
using an Illumina Nextera XT library preparation kit (Illumina Inc, CA) targeting the V3V4 regions of the 16S rDNA. The 16S data were analyzed and visualized using Qiime2
[46, 47]. Greengenes database was used to rule out contamination. The 16S data were
analyzed using custom database for the 14 species and C. difficile 16 rDNA sequences.
The representative sequences were used as query and the 14 species and C. difficile 16
rDNA sequences were used as database for NCBI blast tool, as better resolution at
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species-level was obtained [48]. Statistical analysis was conducted for five species to
determine significant differences within the three groups: control, antibiotic and CDI
treatment. Kruskal wallis test and Dunn’s postHoc test were performed on OTU table
generated for CDI treatment group in R [49]. The Nemenyi postHoc test was also
performed to check for significance [50].
1.2.7

Phenotypic measurement

1.2.7.1 VFA analysis
For the VFA analysis, 800 µl of the cultures were drawn from the reactor groups
from day 2 to day 20 and mixed in 160 µl of freshly prepared 25% m-phosphoric acid.
The samples were centrifuged at 20,000 g for 30 mins and stored at -80°C. 300 µl
supernatant was used for injection in the TRACE1310 GC system (Thermo Scientific,
USA) for VFA analysis. The analysis was performed and plotted in Microsoft Excel.

1.2.7.2 Community-level physiological profiling (CLPP) analysis
To estimate the metabolic activities of the communities formed during the course
of the experiment, community-level physiological profiling was carried out using
Anaerobic (AN) Biolog plates [51, 52]. Cultures obtained from random reactor wells
were plated as quadruplets for days 8, 12, and 20 for each group. CLPP analysis was
performed to determine the ability of the microbial community to utilize 95 carbon
sources during stabilization, after antibiotic addition and after C. difficile inoculation. 1.5
ml culture was centrifuged at 3000G for 1 min to obtain a loose pellet, and it was washed
in 500 µl PBS to remove residual media. After three PBS washes, the pellet was
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resuspended in AN inoculating fluid (optical density at 650 nm [O.D.650] ~ 0.02). 100 µl
of this fluid was inoculated in the AN Biolog plates and incubated at 37°C.

1.3 Results
1.3.1

Abundance mapping

The 14 species in our blend are known to be the prevalent or dominant gut species
among the 20 species in the 13,490-human gastrointestinal metagenomes. In order to
understand the prevalence of these species in CDI patients’ gut and healthy gut, we
performed abundance mapping using a custom database for the 14 species in Kaiju
software. The public metagenomes downloaded contained three groups, the healthy
population (AB- group), patients treated with antibiotics and negative C. difficile
infection (AB+ group) and patients with positive CDI. The CDI group had a higher
population of E.coli and Parabacteroides distasonis indicating that it may be supporting
C. difficile growth. The AB+ group contained Bacteroides caccae, Bacteroides ovatus,
Bacteroides thetataiomicron and Bacteroides uniformis (Fig 1.2). This correlates with the
literature on the Bacteroides spp. being depleted in the CDI patients, indicating the
importance of these species to confer resistance against Clostridium difficile [53].

16

Fig. 1.2. Comparing 14- bacterial abundance in healthy (AB- group), antibiotic
treated (AB+ group) and C. difficile infected (CDI group) individuals from a public
shotgun metagenomic dataset [39]
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1.3.2

Observed patterns in growth measurements

We designed a synthetic blend of 14 gut bacteria previously cultured from
Prevotella-dominated gut. A study has shown these species to be among the 20 prevalent
or dominant in the 13,490-human gastrointestinal metagenomic samples. The O.D. and
pH were taken as the growth measurements for the experiment (Fig. 1.3). The optical
density growth measure helps estimate bacterial load and analyze the patterns in each
group. The figure shows the O.D. values observed from day2 – day 23 in the three reactor
groups. The O.D. measurement in control group appears to be constant throughout all the
days, while the O.D. in antibiotic and CDI treatment group appears to reduce from day 10
to 12 and starts increasing from day 14 onwards. Even after antibiotic addition at day 8,
the cells appear to stabilize in the reactor groups suggesting that none or not all bacteria
were killed due to clindamycin. O.D. however, cannot differentiate between live or dead
cells and hence cannot be used to correlate the number of living cells in the groups [54].
The pH is the second growth measurement for the experiment which helps to
determine the changes in the media conditions after the addition of synthetic blend in
plain media, after antibiotic perturbation and after C. difficile addition. The pH
measurements are all observed to be in the range of 5.5-6.4. There is an increase in pH in
antibiotic and CDI treatment group at day 9, one day after the antibiotic administration.
The pH increases from ~5.8 to ~6.3 in both the groups and comes back to ~5.8 on day 10.
pH gives an idea about the acidity conditions of the media and the possibility of the type
of bacteria growing in the medium. A low pH indicates acidophilic bacteria thriving in
the medium.
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Fig. 1.3. The growth measurements for the synthetic gut consortium bioreactor
samples (a) Optical density over the period of 22 days and (b) pH change over the period
of 22 days.

1.3.3

Microbial succession using amplicon sequencing

Ecological succession is a time-series change or transition of a community; here a
microbial community observed in a particular space [55]. The 16S analysis shows the
succession of microbial patterns in the three groups under three different environmental
conditions. There was no contamination in the experiment. This was ruled out using the
greengenes database. The control group contains the Mix14 consortia that were allowed
to grow without any perturbations in 6 wells/replicates (Fig 1.4). The consortia start to
stabilize from day 5 with E. coli and F. sacchanivorans being dominant from day 2
through day 23. R. faecais abundance increases in from day 7 through day 23. Relative
abundance of B. obeum appears to decrease drastically after day 4. The relative
abundance of B. dorei, B. uniformis, B. longum, P. distansonis and P. merdae reduces to
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zero after day 2. Overall, it appears E. coli, F. sacchanivorans, B. thetataimicron, B.
caccae and C. aerofaciens are present in all the wells from day 2 to day 23. The
inoculum shows only 12 out of 14 species of Mix14. It was difficult to identity B.
vulgatus and B. ovatus by the 16S analysis, possibly due to close relatedness of the
Bacteroides species. It may be challenging to obtain a species-level resolution with the
amplicon sequencing.
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Fig. 1.4. The microbial succession of the 14 species over the period of 23 days in the
control group.
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Antibiotic treatment group containing the Mix14 consortia was treated with
antibiotic from day 8 to 12. C. difficile was introduced on day 20 in 6 wells (replicates).
The consortia start to stabilize from day 5 with E. coli having almost constant abundance
from day 2 through day 23. It can be seen that R. faecis abundance increases in 4 wells
(replicates) from day 7, but it appears to reduce after one day of antibiotic treatment and
is lower until day 12. Relative abundance of B. obeum decreases drastically after day 4
and does not appear to be affected by antibiotics as similar conditions were observed in
control group. The relative abundance of B. dorei and P. distasonis reduces to near zero
after day 2 until day 9 and appears to increase after day 10. The relative abundance of B.
uniformis, B. longum, and P. merdae appears to reduce to zero after day 2. Relative
abundance of F. saccharivorans drastically reduces after 48 hours of antibiotic
administration and appears to be zero after day 17. C. aerofaciens is present day 2
through day 23, but the relative abundance is very low as compared to other bacteria.
The relative abundance of B. thetataimicron, and B. caccae appear to increase
after 24 hours after antibiotic administration (Fig 1.5). Overall, it appears B.
thetataimicron, B. caccae, B. dorei and P. distasonis increase after antibiotic
administration while F. saccharivorans and R. faecis appear to reduce in the presence of
antibiotic.
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Fig. 1.5. The microbial succession of the 14 species over 23 days in the antibiotic
treatment group.

CDI treatment group contains the Mix14 consortia which was treated with
antibiotic from day 8 – 12. C. difficile was introduced on day 13 in 6 wells (replicates)
(Fig 1.6). CDI treatment group results are similar to antibiotic treatment group with the
exception of R. faecis, B. dorei and B. thetataimicron., appear to be low as compared to
antibiotic treatment group after antibiotic treatment.
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Fig. 1.6. The microbial succession of the 14 species over the period of 23 days in CDI
treatment group.

Five species: E.coli, Bacteroides caccae, Bacteroides thetataimicron
Parabacteroides distanosis and Bacteroides dorei appear to have a drastic increase or
decrease in the antibiotic and CDI groups (Fig. 1.4, 1.5 and 1.6). Therefore, we checked
whether the differences were significant among the three groups of these species. The
Kruskal-Wallis test and Dunn’s postHoc test revealed, E.coli, Fusicatenibacter
saccharivorans and Parabacteroides distanosis exhibited significant differences across
all three groups while the Bacteroides caccae and Bacteroides thetataimicron species had
significant differences only between two groups with the antibiotic and CDI treatment
groups being similar (Fig. 1.7).
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Fig. 1.7. The boxplots depicting significant groups from the postHoc Dunn’s test
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1.3.4

Phenotypic measurements

1.3.4.1 Volatile fatty acids (VFA) analysis
Volatile fatty acids (VFA)/ short-chain fatty acids (SCFA) are end point
metabolites produced by bacteria which can confer protective effects against enteric
pathogens [56]. Here, we analyze the main VFA production, acetate, propionate and
butyrate. In Fig. 1.8a, the concentration of acetate appears to decrease slightly in the
control group after day 12 while it decreases drastically from ~30 mM to < 10 mM in
CDI treatment group. These groups were infected with C. difficile on day 13. In Fig 1.8b,
the concentration of propionate appears to stay constant <10 mM in control and antibiotic
treatment group while the propionate concentration increases significantly by ~24 mM in
CDI treatment group after day 12. The concentration of butyrate increases significantly in
CDI treatment group after Day 12 while overall the butyrate production appears to be at
lower concentrations < 4 mM in the other groups (Fig 1.8c). Overall, the group s appear
to have VFAs which can be one of the reasons C. difficile is not able to colonize
following the antibiotic treatment in group antibiotic and CDI treatment group.
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Fig. 1.8. VFA production (average + standard error) (a) acetate, (b) propionate and
(c) butyrate on days 8 (stabilization) , 12 (antibiotic cessation) and 20 (endpoint) for the
bioreactor control, antibiotic and CDI treatment groups.
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1.3.4.2 Community-Level Physiological Profiling (CLPP) analysis
The second phenotypic measurement performed was the community-level
physiological profiling (CLPP). CLPP is a technique used to assess the sole carbon
utilization patterns of a community. It is useful in understanding how microbes behave in
a community via the utilization of a particular substrate over space and time [52, 57].
This information can assist in determining the function of a particular bacterial mix
community. Fig. 1.9 shows the utilization patterns for 95 different carbon sources of the
community formed at day 8, day 12 and day 20 in the three bioreactor groups. Previously,
carbon utilization patterns for the 14 bacteria were performed from monocultures [38]. A
comparative analysis of the Biolog results is displayed in Fig 1.9. The data shows the
utilization patterns of the community formed on a particular day mainly the stability
condition at day 8, the post-antibiotic condition at day 12 and the period after C. difficile
inoculation at day 20. The community formed after day 12-post antibiotic addition was
capable of utilizing mannitol, sorbitol and succinate [38, 58] which are the substrates that
C. difficile use to produce infection.
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Utilization by one bacteria or the community
Utilization by >1 bacteria
No utilization

Fig. 1.9. Carbon utilization patterns of the consortia in the minibioreactor under
different conditions and the utilization pattern of individual 14 bacteria forming the
defined blend. The last row is the sum of utilization of all individual bacteria and the pink
box denotes if the substrate is utilized by more than one bacterium.
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1.4 Discussion
Enteric infections caused by Clostridium difficile, Clostridium perfringens,
Escherichia coli, Staphylococcus aureus, Vancomycin-resistant enterococcus (VRE),
Vibrio cholera, and Salmonella typhimurium are major health problems around the world
[59]. Thus, many therapeutics such as the fecal microbiota transplant (FMT) and
synthetic microbial blends have been given more importance over the past few years for
treating recurring infections after antibiotic intake [60, 61]. For centuries, people have
been using live microorganisms which yield health benefits when administered in the
correct amounts. These are termed probiotics and have been used as a treatment to cure
gastrointestinal disorders [62]. There are single organisms as well as composite probiotics
such as VSL#3 [62, 63]. Many studies use selected bacterial mixes to reduce CDI [32, 33,
38]. Also, FMT has been shown to have efficacy with reducing recurrent C. difficile
infection. However, FMT has many social and ethical issues [64]. Therefore, probiotics
or a defined bacterial mix is an alternative therapeutic method for reducing CDI.
We know that the interpersonal microbiota varies and this variation can cause
different resistance capabilities towards gut enteric pathogens [65]. Therefore, it becomes
necessary to study the presence of the most prevalent or common bacteria across the
human population and discern which organisms may confer resistance against CDI.
Therefore, in our study, we developed a blend of 14 gut bacterial species, which are the
most prevalent species in the human healthy gut across the Bacteroidetes enterotype
population [16]. We hypothesize that this blend will produce a stable community and
confer resistance against C. difficile after antibiotic perturbation in the host. We believe
the presence of a few key species among these 14 species may be responsible for
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inhibiting Clostridium difficile. In our study, we determined the population structure and
succession of our mix of 14 species or blend under normal conditions, after antibiotic
perturbation and following the addition of C. difficile after antibiotic perturbation in a
continuous flow system.
The abundance of these 14 species in the public metagenome dataset corroborates
with the data obtained from the 16S analysis in the minibioreactor experiment (Fig 1.4,
1.5 and 1.6). The presence of E.coli in higher abundance in the C. difficile population
relates to the positive relationship between the two species while most of the Bacteroides
species have an inverse effect on C. difficile growth. In the minibioreactor experiment,
Bacteroides caccae and Bacteroides thetataimicron appear to be significant bacteria in
the antibiotic group as well as increase in the CDI group. Bacteroides species may be
playing a role in reducing CDI but several studies have shown a deficit in Bacteroides
species after antibiotic treatment [32, 66-68]. However, our blend appears to have an
increase in the Bacteroides species after the addition of antibiotics. Further study may
reveal the mechanisms underlying how the Bacteroides species are able to persist even
after antibiotic addition.
The growth measurements determined by optical density and pH were measured
from day 2 to day 23 of the bioreactor experiment. These measurements relate to the
bacterial succession of the blend. The sudden increase in pH after antibiotic addition can
cause a favorable environment for C. difficile growth. Therefore, a reduced pH after day
11 may be one of the possible reasons that C. difficile was not able to invade the blend.
Another reason may be related to the VFA production by the bacterial species. It has been
known that VFAs have a protective effect on a healthy gut and VFAs are reduced in CDI
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patients [25, 69]. A study showed depletion in butyrate production and Bacteroides spp.
in CDI patients [53]. Another study in mice has shown protection against C. difficile by
butyrate [70]. However, butyrate did not interfere with the colonization of C. difficile in
another study, while concentrations above 50mM limited the growth. Thus, butyrate may
have a protective effect by creating physiological changes in the host. The VFA
propionate has been known to have resistance against Salmonella by Bacteroides spp [56,
71]. This may be one of the possible ways Mix14 inhibits C. difficile colonization
because an increase in the Bacteroides spp. Further research is needed for determining
the effects of VFA on CDI while using Mix14 in vivo, such as germ-free mice.
The CLPP analysis provides us with the carbon utilization behavior of a
community formed at a particular time-point. It can be observed that for the community
formed on day 12 after the antibiotic treatment, the microbes can utilize mannitol,
sorbitol and succinate [38, 58]. These substrates are known to be utilized by C. difficile to
produce infection. Utilization of these substrates by the microbial community after
antibiotic perturbation could be one of the reasons for the C. difficile inhibition in the
CDI treatment group. The behavior and function of bacteria grown as a monoculture and
in a community, could be helpful for future prediction studies for the synthetic
consortium.
This study provides a framework for further research work in C. difficile
colonization resistance by the bacterial blend. One aim is to create dysbiosis conditions in
vitro and in vivo and test the efficiency of this blend as a therapeutic agent. Using this
bacterial blend as a method of preventing dysbiosis is also important. Mix14 can also be
a model for studying the cooperation and competition between the species and elucidate
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the natural community interactions for conferring colonization resistance against C.
difficile. Studying the key ecological and evolutionary interactions in a simplified system
can help simplify the understanding of colonization resistance of complex gut
microbiome. The utilization of preliminary data on mono-culture assays, the 16S
abundance data, growth curve, phenotypic assays such as VFA production, communitylevel physiological profiling and metabolomics can be useful in ecological-based
modeling, genome-scale metabolomic networking, population dynamic models,
prediction community functions and microbe-microbe interactions [72, 73]. The results
show a promising effect of this blend as a therapeutic and as a model to study
colonization resistance.
1.5 Conclusion
Our in vitro minibioreactor studies showed the successful inhibition of
Clostridium difficile by the synthetic gut consortium consisting of 14 gut bacteria. The
population formed after antibiotic perturbation by clindamycin was able to confer
resistance against C. difficile. Future work on determining the mechanisms and ability of
the blend to inhibit or reduce the pathogen in vivo mice models may be useful in
deciphering host physiological and immune responses.
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2. CHAPTER 2 : BIOINFORMATIC ANALYSIS REVEALS GUT MICROBES
WITH POTENTIAL TO DEGRADE QUERCETIN AND THEIR POSSIBLE
ROLE IN GENERATING ANTICANCER EFFECTS
2.1 Introduction
2.1.1

Flavonoids and their dietary occurrences

Flavonoids are polyphenolic compounds ubiquitously occurring in food sources
from plants. Some common food and beverages with flavonoids are onion, red cabbage,
celery, citrus fruits, berries, tea, and red wine [74]. There are over 6000 flavonoids
identified and have been classified into six main subclasses [75]. They are mainly
associated with broad spectrum of health-promoting characteristics, especially their
antioxidant properties. Flavonoids occur at varying levels in fruits, beverages and
vegetables and the different subclasses have been associated with different actions on the
human body [76]. They have antimicrobial, anticarcinogenic, anti-inflammatory,
antidiabetic, estrogenic, and antioxidant properties [77, 78]. Many animals,
epidemiological and cellular studies have shown the potential positive health effects of
flavonoids [79, 80]. Flavonoids have inverse effects in diabetes, mental illness, cancers
and cardiovascular diseases [81-84].

Flavonoids are the largest class of dietary polyphenols, which have been used as
nutraceutical ingredients due to their health benefits [85]. Their structure includes two
phenyl rings and one heterocyclic ring and they are classified into six major subclasses:
flavonols, flavanones, flavanols, anthocyanins, flavones and isoflavones [86, 87]. They
are commonly found in plants and play a critical role in plant regulation during abiotic or
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biotic stress. Plants have varying concentrations of flavonoids depending on the
environmental conditions such as temperature, exposure of plants to sunlight and day
length [88]. The most common subclasses found in food are flavonols, flavanones,
flavanols, and flavones and they are usually found in glycoside forms in plants.
Glycosylation of flavonoids increases their water and photo stability [89, 90]. The
common glycosides are quercetin-3-O-rutinoside found in tea [91] while capers are high
in flavonols like kaempferol 3-rhamnosyl-rutinoside, quercetin 3-rutinoside, and
kaempferol 3-rutinoside [86, 92]. Apigenin-7-O-glucoside is found in chamomile [93]and
apiosylglucoside malonyl conjugates were found in steam celery and parsley [94]. Citrus
juices have both flavone O- and C-glycosides and flavanone-O-glycosides [95]. Berries
and soybeans are known to be rich in isoflavonones and anthocyanins.
The flavonoids are metabolized in the gastrointestinal tract (GIT), liver, and the
gut microbes in the large intestine. The flavonoids become available by three known
possible events: 1) absorption across the GIT, 2) hepatic metabolism and 3) action of gut
microbes [96]. Even with three possible ways of metabolism, the gut microbes degrade
flavonoids with multiple possible enzymes and pathways. With a vast number of
flavonoids in nature and many possible ways of its metabolism, it becomes important to
understand the metabolism and bioavailability of flavonoids in the human body. Studying
the bioavailability and mechanisms by which it induces positive effects can help us
determine the optimum dosage for a favorable health effect.
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2.1.2

Quercetin and its health effects

Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is the major representative of the
subclass flavonol. Quercetin is a glycone and is found mostly in glycosylated form in
apples, berries, capers, Brassica vegetables, nuts, onions, grapes, shallots, tea, tomatoes,
flowers, leaves and bark. Medicinal plants such as Sambucus canadensis, Gingko biloba
and Hypercium perforatum also contain quercetin [97-99]. The lowest concentration of
quercetin occurs in tea (2mg/100g) while the highest occurs in raw capers (234mg/100g)
[100]. The dietary intake of quercetin varies depending on countries and the food sources.
The estimated flavonoid intake ranges from 50 to 800mg/day with 75% being quercetin
[99, 101]. For example, the major source of quercetin intake in Italy is wine, while in
Finland, United States and Greece, intake mostly comes from apples and onions [102]. In
Australia, the main sources of quercetin are green and black tea [103]. Due to its
widespread abundance in food sources, it is one of the main flavonoids studied for its
properties. Quercetin has tremendous potential therapeutic effects in the medical field to
improve human health [104, 105]. It is also being studied as a nutraceutical [85].
Quercetin is known to have various pharmacological usages due to its antioxidant,
antiproliferative, antimicrobial, cardioprotective, and anti-estrogenic effects [106].
Quercetin has the potential to inhibit laryngeal cancer as well as ovarian cancer [107,
108]. Many pathways have been proposed to treat various cancers [109-111]. Quercetin is
known to chelate metals and scavenge oxygen free radicals. The in vivo antioxidant
activity of quercetin is mainly displayed through the signal transduction pathways,
reactive oxygen species (ROS) and effects on glutathione (GSH) [105]. Oxidative stress
can lead to acute and chronic disorders like inflammation, diabetes, and atherosclerosis.
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In the case of atherosclerosis, quercetin modulates lipid metabolism by reducing
oxidation low-density lipoprotein (LDL) which induces the condition [112]. Quercetin
shows protective effects on acute myocardial infraction in rats [113]. It can also be used
in alleviating depression. A study has shown that quercetin prevents neural damage and
lowers hippocampal inflammatory and oxidative responses [114]. The urotoxicity
induced by cyclophosphamide can also be prevented by quercetin [115]. In the context
of gut health, a study has shown the potential of quercetin to be used as a prebiotic to
combat gut dysbiosis after antibiotic treatment [116]. Another study showed the dietary
quercetin increases gut diversity and alleviates Citrobacter rodentium infected mice
colitis [117]. The study suggests the benefits of quercetin in restoring gut microbial
balance and activating the immune system to lower inflammation. The use of quercetin
for gut health and its ability to restore oxidative properties can be useful in medicinal
applications.
2.1.3

Possible enzymes involved in quercetin metabolism

Quercetin can be metabolized either by hydrolysis and absorption in the stomach,
the small intestine, the liver, or by the gut bacteria in the intestine [96]. Metabolism and
absorption efficiency is influenced by the form of quercetin. A study showed that
quercetin in its aglycone form is easily absorbed in the stomach of rats, but when it is
aglucoside, it is easily absorbed in the small intestine [118]. In its glycosylated form,
quercetin is easily absorbed through the sodium-dependent glucose transporter 1
(SGLT1) located in the apical membrane of small intestinal villi [119]. Quercetin
glycosides can also be transported by hydrolysis from the lactase phlorizin hydrolase
(LPH), a glycoside hydrolase on the outside of the brush border membrane of the small
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intestine [120]. This enzyme liberates quercetin which can be absorbed across the
intestine. The quercetin reaching the large intestine is metabolized by the intestinal
bacteria. Degradation of quercetin by bacteria Eubacterium ramulus, Flavinofractor
plautii, Eubacterium oxidoreducens has been reported [121-123]. Quercetin is degraded
by gut bacteria into at least seven metabolites [124]. The possible metabolites produced
after Eubacterium ramulus and Flavinofractor plautii degradation are phloroglucinol and
3,4-dihydroxyphenylacetic acid via taxifolin as the intermediate product [122, 125]. The
enzyme quercetin 2,3-dioxygenase or quercetinases also acts on quercetin to form 3,4dihydroxybenzoic acid, also known as protocatechuic acid (PCA) and 2,4,6trihydroxybenzoic acid. Quercetinases have been found in fungi Aspergillus niger,
Aspergillus flavus, Fusarium oxysporum and bacteria Bacillus subtilis, Streptomyces sp.
FLA [126-128]. Pirin-like proteins have been identified to have quercetinase activity,
however they have very weak homology to the sequences of quercetinases identified
from B. subtilis and Streptomyces sp [129]. The degradation of quercetin to PCA may
involve multiple pathways. One such pathway is conversion of quercetin to PCA via 4hydroxybenzoic acid as the intermediate [124]. Phloretin hydrolase enzyme from
Flavinofractor plautii may be able to degrade quercetin which structurally similar to
phloretin [130]. Phloretin hydrolase is also characterized in Eubacterium ramulus, a
bacteria which is also capable of degrading quercetin [131].
Although studies have shown quercetin metabolism by gut bacteria as well as
determined products of quercetin after degradation in the intestine, the exact mechanism
of degradation of quercetin, enzymes or complete pathways related to quercetin
metabolism in the large intestine has not yet been elucidated. Degradation of quercetin
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possibly involves multiple enzymes and pathways by the gut bacteria. For this study, we
chose a well-characterized enzymes for sequence homology detection in known cultured
gut bacteria. The three enzymes are quercetinase from Bacillus subtilis, and Streptomyces
sp. FLA, phloretin hydrolase from Flavinofractor plautii and Eubacterium ramulus, and
pirin-like protein known for quercetinase activity from Pseudomonas stutzeri [126, 127,
129, 130]. The genes and protein sequences have been used for blast and hmmer search
for homology detection. Apart from the enzymes, the yxaGH operon [132]from Bacillus
subtilis consists of qdoR, qdoI (quercetinase) and yxaH genes which were separately used
for blastn analysis.
2.1.4

Gut microbial metabolism of quercetin

The dietary polyphenols are known to be majorly accumulated in the large
intestine (90-95%) while 5-10% is absorbed in the small intestine [133]. Thus, the major
portion of the polyphenols are subjected to microbial degradation for absorption in the
human body. The absorption of these polyphenols by gut microbes may have significant
effects on these polyphenols at their target site as well as the bioavailability for the body.
Therefore, the ability of these polyphenols to have effects on gut microbiome becomes an
important research area to study. Quercetin being the major representative of flavonols
has been studied for its role in influencing gut beneficial modulation and its health effects
[117, 134-137]. Many of these studies show varying effect on the microbiota, which may
be due to the host-related multiple compounding effects from the in vivo studies. Thus, in
vitro studies can be helpful to determine microbe-microbe interactions and study the
metabolites and microbial biotransformation in an accurate manner [134, 138]. Although
studying the impact of quercetin on intestinal microflora for metabolism of quercetin is
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useful, there is a need to understand the species/strains involved in the metabolism as
well as the enzymes and metabolic pathways for the biotransformation of flavonoids
(quercetin). Many bacterial species are known to degrade glucosides of quercetin,
however little is known about the bacterial species involved in quercetin transformation
[96, 139]. A study was performed to isolate and identify bacteria in human gut for
metabolizing quercetin in an in vitro model and seven bacteria from the fecal samples;
Bacteroides fragilis, Clostridium perfringens, Enterococcus gilvus, Escherichia coli,
Lactobacillus acidophilus, Stretococcus lutetiensis, and Weissella confusa had the
ability to transform quercetin. [140]. In this study, Bacteroides fragilis and Clostridium
perfringens were found to have the highest degrading ability. This suggests quercetin is
unable to inhibit pathogen C. perfringens. Apart from the seven bacteria, the species;
Eubacterium ramulus, Flavinofractor plautii have been known to degrade quercetin
[122, 125, 139]. Since quercetin is such an important dietary polyphenol, it is important
to isolate and identify more gut species responsible for quercetin transformation.
2.1.5

Dose-dependent, media conditions and Toxicity

Most of the studies carried out have significant variations on the effective doses as well
as the model used for the studies, which may be the reason for differences in the
mechanistic understanding of quercetin. One such example is the use of quercetin and its
ability to protect against breast cancer [141, 142]. One study showed doses of 2% and 5%
quercetin reduced tumor development in chemically induced mammary cancer in rat
models [143] while another study showed quercetin was unable to confer protection
against breast cancer at a dose of 2.5 g/kg food [144]. Besides being dose dependent,
quercetin is degraded by bacteria differently depending on the media conditions. For
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example, E. ramulus degraded quercetin in presence of glucose while E. oxidoreductans
degrades in presence of formate and H2 [122, 123]. Also, E. ramulus exhibited crossfeeding mechanism with B. thetataimicron in the presence of starch indicating its strict
requirement of glucose in co-metabolizing quercetin [121].
The health benefits of quercetin can be appealing to many health-conscious
people but exceeding the amount of dietary quercetin or any flavonoid can lead to toxic
effects in the human body. Studies have shown potential toxicity of quercetin i.e.,
mutagenicity, mitochondrial toxicity, inhibition of key hormone metabolism enzymes and
prooxidant activity [145, 146]. These studies shed light on the use of quercetin for drug
development programs as well as a need to understand the mechanisms of molecular and
microbe interactions at a deeper level in order to guarantee the safety and efficacy of
quercetin.
2.1.6

Importance of this study

From the literature, it is evident that E. ramulus and F. plautii transform quercetin
to 3,4-dihydroxyphenylacetic acid (DOPAC), which has antiproliferative activity in colon
cancer cells [147]. However, the enzymes and pathways are unknown. The second
enzyme quercetinases transforms quercetin into 3,4-dihydroxybenzoic acid, also known
as protocatechuic acid (PCA) and 2,4,6-trihydroxybenzoic acid. The product 2,4,6trihydroxybenzoic acid is also known to be anti-proliferative agent [148]. However, no
information on bacterial metabolism yielding these products is known. Therefore, it is
important to elucidate the microbes involved and the pathway in quercetin
biotransformation.
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For this study, we focus on the possible metabolisms by the action of gut
microbes in the large intestine for the subclass flavonols with a special focus on quercetin
metabolism. One of the objectives is to determine the presence of homologs for quercetin
degrading enzymes in the genomes of the known cultured gut bacterial species using
bioinformatic analysis. The second objective is to find the abundance of predicted
bacterial species known to have the homologs for quercetin degrading enzymes in the
healthy and CRC individuals from the publicly available shotgun metagenomes. This will
help us understand the enrichment and possible link of the bacteria to induce potential
health effects by metabolizing quercetin to obtain beneficial products.
2.1.7

Objectives of this study

•

Screen for possible enzymes and operons in the gut microbe genomes

•

Screen for abundance of the bacteria predicted to have quercetin- degrading
ability in the CRC and healthy datasets

•

Check for significant bacteria in the healthy and CRC datasets
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2.2 Methodology
2.2.1

General Workflow

Fig 2.1 depicts the general workflow carried out in this study. The goal is to
predict the quercetin degrading gut-bacteria by the homology-based analysis for six
enzymes and find a possible link of the bacteria with CRC or healthy conditions.

BLAST
analysis

Fig. 2.1. General workflow of the bioinformatic analysis performed for this study
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2.2.2

Datasets – genomes and metagenomes used for this study

In total, 1066 cultured gut bacterial genomes were chosen for this study based on
a literature search and our 102-gut library [38, 149, 150]. There were 860 out of the 1066
bacterial genomes available on refseq (30th September,2020). The protein files were
downloaded from NCBI-refseq via linux- command line. The protein files were
concatenated to get protein query databases for blast analysis.
To calculate abundance of certain gut bacterial genomes in the CRC and healthy
individuals, public shotgun metagenome datasets were downloaded from five CRC
studies [151-154]. The five studies have been conducted in countries Austria, China,
France, Germany and India (Table 2.1).
2.2.3

Protein sequences for homology search

To create the blast database, genes for quercetin 2,3- dioxygenase, flavonereductase, chalcone isomerase, enoate reductase, pirin-like protein and phloretin
hydrolase were selected (Table 2.2). The blast analysis for protein sequences was carried
out using standalone NCBI-BLAST software. Databases was created for each enzyme
using the makeblastdb command. The resulting output files were parsed in R using
parameters for 30% percent identity, 80% query coverage and 1e-10 e-value, respectively
[155]. In total 64 bacteria were selected to be a subclass of possible quercetin degraders.
The 64 bacteria obtained from the blast hits were used for abundance mapping in the
public metagenome datasets.
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2.2.4

Statistical analysis for the quercetin-degrading gut bacteria in healthy
and disease conditions

The public metagenomes were downloaded using the prefetch and fastq-dump
commands from the Sra-toolkit software [40].The fastq files were processed to remove
human host reads using metawrap read-qc module. The protein files of bacteria predicted
to degrade quercetin were used for building a custom database for Kaiju [42]. The
mapping of the bacteria on metagenomes was done using Kaiju software. The abundance
output obtained from Kaiju were parsed in R to perform ANOVA statistical test on each
bacterial abundance and condition for each country dataset. Bacterial abundance were
randomly checked from each dataset for ANOVA assumptions. Some of them met the
assumptions. Therefore, more analysis needs to be performed in future. After obtaining
significant bacterial abundance in each country, we checked for its relative abundance in
healthy or in CRC conditions. Out of the 64 bacteria, 11 bacteria were significantly (p <
0.05) greater in healthy individuals in either one or more countries while 44 bacteria were
significantly (p < 0.05) greater in CRC individuals. All the heatmaps were generated
using online Morpheus software (https://software.broadinstitute.org/morpheus).
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Table. 2.1. Public metagenome datasets for CRC and healthy individuals based on
countries.
Country

Bioproject number

Number of samples

Austria

PRJEB7774

China

PRJEB10878

France

PRJEB6070

Germany

PRJEB6070

India

PRJNA531273, PRJNA397112

Healthy : 63
CRC : 46
Healthy : 53
CRC : 75
Healthy : 64
CRC : 50
Healthy : 38
CRC : 5
Healthy : 30
CRC : 30

Table. 2.2. Reference sequences of enzymes degrading quercetin used for BLAST
analysis.

Protein sequence

Reference Species

Accession no.

phloretin hydrolase

Flavinofractor plautii

OXE48401.1

Eubacterium ramulus

AAQ12341.1

Bacillus subtilis

P42106

Streptomyces sp. FLA

CAJ81053.1

Escherichia coli

P46852

Pseudomonas psutzeri

EHY79687.1

quercetin 2,3- dioxygenase

pirin-like protein
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2.3 Results
2.3.1

BLAST analysis reveals subset of bacteria capable of degrading quercetin

The literature review revealed three possible enzymes capable of quercetin
degradation (Fig 2.2) [129, 130, 156]. From the literature, quercetin 2,3-dioxygenase
(quercetinase) is known to metabolize quercetin into 2,4,6-trihydroxybenzoic acid and
3,4-dihydroxybenzoic acid while phloretin hydrolase is one of the proposed enzymes
capable of degrading quercetin in Flavonifractor species [130]. The pirin-like protein is
known to have quercetinase activity in E. coli and P. psutzeri. Therefore, to predict a
subset of gut bacteria from the known cultured gut bacterial species we chose query
sequences of the three enzymes: quercetinase, phloretin hydrolase and pirin-like protein.
For the BLAST database, we selected two query protein sequences for each enzyme
(quercetinase, phloretin hydrolase and pirin-like protein). Template sequences for
quercetinase were taken from B. subtilis and Streptomyces sp. FLA while for phloretin
hydrolase were selected from E. ramulus and F. plautii. Query sequences for pirin-like
protein were selected from E. coli and P. psutzeri. The blastp analysis (p-ident >= 30%,
qcovs >=80%, e-value>=1e-10) revealed 32, 39 and 335 bacteria with quercetinase,
phloretin hydrolase and pirin-like protein homologous proteins respectively (Table 2.3).
In total, 64 bacteria were chosen as the subset for further analysis for abundance
mapping and statistical testing in the public datasets. Since, pirin-like protein are known
to exhibit quercetin- degrading ability but the biological role is yet to be studied, we
excluded the bacteria which are uniquely predicted to have this protein. Out of the 64
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bacteria, 6 bacteria; Bacillus megaterium, Clostridium butyricum, Olsenella sp.,
Paenibacillus polymyxa, Pseudomonas fluorescens and Rhodococcus erythropolis are
predicted to have all three enzymes (Fig 2.3 & 2.4). While 14 out of the 64 are known to
have quercetinase and pirin-like protein and 10 out of the 64 are known to have phloretin
hydrolase and pirin-like protein (Fig 2.3 & 2.4). Only one bacterium; Enterocloster
clostridioformis commonly have both phloretin hydrolase and quercetinase enzyme
homolog.

Fig. 2.2. Possible degradation pathways for quercetin.
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11
quercetinase
1

14
6

22
phloretin
hydrolase

305

10
pirin-like
proteins

Fig. 2.3. Venn diagram depicting total number of bacteria following BLAST analysis.
It shows the number of gut bacteria containing either one of the enzymes as well as
number of bacteria sharing the enzymes.

2.3.2

Abundance mapping for the subset of gut microbes able to degrade
quercetin

Some bacteria can degrade quercetin to produce anticancerous metabolites.
However, it is not clear how many gut bacteria are capable of transforming quercetin and
to what extent the metabolites produced have an impact on health. This study proposes
the possibility of the subset of gut bacteria which may be capable of quercetin
transformation. Up until now, quercetin metabolites are known to have anti cancerous
effects, therefore we checked for the abundance of the quercetin degraders in the public
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datasets of CRC patients and healthy controls (Table 2.1). Fig 2.4 shows bacterial
abundances in each country and condition dataset as well as the presence of predicted
homologs and the bacteria which are significant. The significance was calculated using
the ANOVA statistical test in R for each country dataset based on the condition. In total,
55 bacteria were found to be significant (p <0.05) in either one or more public shotgun
datasets. Further, we checked if the significant bacteria were higher in the healthy or
CRC conditions. Most of the bacteria showed higher abundances which were significant
in CRC conditions, however overall, the data seemed to not follow a definite pattern (Fig
2.5). We focused on bacteria which were present only in healthy conditions in one or
more datasets. From Fig 2.5, it can be observed that 11 bacteria are present in healthy
conditions. Variations in the significance level in conditions can be due to multiple
factors including geography, diet, genetic makeup, etc.
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Fig. 2.5. Presence of significant bacterial abundance in each CRC country dataset

where red square denotes higher in CRC condition and green denotes higher abundance
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Fig. 2.4. Heatmap denoting abundance of the 64 quercetin-degraders, the presence of

the three enzymes in each bacterium and the significant bacteria by ANOVA analysis (p
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2.3.3

Phloretin hydrolase gene was observed in majority of the health-related
bacteria

The 11 bacteria from the analysis were observed to be higher abundance in
healthy samples in at least one of the datasets. We further checked the presence of the
protein homologs (quercetinase, phloretin hydrolase and pirin-like protein) in the 11
bacteria (Fig 2.6). Out of the 11 species, 10 bacterial genomes had the phloretin
hydrolase enzyme from the BLAST analysis while Microbacterium hydrocarbonyxdans
had only quercetinase enzyme homolog (Fig 2.6). Olsenella sp. had presence of all three
enzymes while Paraprobacterium paucivorans had phloretin hydrolase and pirin-like
protein homologs. These 11 bacteria can be used for further screening of their quercetin
degrading capability and their role to produce bioactive metabolites in prevention of
CRC.
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Fig. 2.6. Presence of the three enzymes in the bacteria higher in healthy individuals.
The blue squares denote presence of the enzyme.
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2.4 Discussion
Quercetin is the major flavonol in the flavonoid subclass and numerous researchers
study its beneficial effects on the human body. However, the role of quercetin as a
mediator or shaping the human gut microbiome of the regular flavonoid-consuming
individuals as well as its role in abating the risks for pathologies is poorly understood.
Bacteria such Flavinofractor plautii (Clostridium orbiscindens) and Eubacterium
ramulus are known to degrade quercetin to produce useful metabolites. Therefore, it
becomes important to study other quercetin degraders in the gut to understand and predict
health outcomes. This study forms a baseline providing the possible quercetin degraders
based on quercetin-degrading enzyme homologs. Apart from the role of the gut bacteria,
the enzymes and pathways of quercetin degradation are not clearly understood. Few
bacteria are capable of degrading quercetin through quercetinase, while bacteria like F.
plautii and other Flavinofractor species are predicted to degrade quercetin by phloretin
hydrolase [130]. The mechanisms of degradation, as well as the important species in the
gut that are active in quercetin degradation, also varies with the dietary intakes. A study
showed high abundance of Flavinofractor species in fecal samples when mixed with 7N
minimal media (20mM sodium acetate) and quercetin, while E. ramulus favours media
rich in glucose for co-metabolizing quercetin [121, 130]. The dietary factors therefore
become one of the compounding factors while studying the effect of gut microbiome in
quercetin metabolism.
This study highlights differences with respect to the abundances and significant gut
species in different geographical locations of the CRC datasets. Although these studies
did not include any dietary information or use of quercetin by the individuals, the overall
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variations in the abundances of the quercetin degrading species might still be related to
the dietary effects.
Quercetin can be studied as either a mediator in the regular flavonoid intake of
individuals and its effect on the gut microbiome and overall metabolic response, or as an
effect modifier [157]. For example, results of this study show that the bacteria E. ramulus
and F. plautii have a significantly higher abundance in the Indian population. One of the
reasons of their population increase maybe due to the elimination of their competition
due to the cancer environment in the gut. Since it has been known that both E. ramulus
and F. plautii can metabolize quercetin into beneficial metabolites, phloroglucinol and
DOPAC [122, 125], quercetin may have some effects on the CRC condition owing to a
relative high abundance of these bacteria in CRC patients. It is, however, difficult to
propose from just one dataset. The datasets of the significant quercetin degraders also
show variations. Therefore, it is important to conduct in vitro or in vivo experiments.
From our study, we propose 11 bacteria which are found to be higher in at least one
of the datasets. It can be seen that 10 of the bacteria have phloretin hydrolase homologs,
thus these bacteria may actually be helpful not only in quercetin metabolism but also
phloretin metabolism, another flavonoid. The bacteria Lactobacillus reuteri is a probiotic
which showed effectiveness in modulating pathways in the pathophysiology of diseases
like CRC when pre-cultivated with mucin [158]. This bacterium can be used as a model
to understand the effect of quercetin metabolism and its role in cancer prevention.
Similarly, Anaerostipes hadrus, and Roseburia sp. are major butyrate producers in the
gut [159]. These species are therefore beneficial for the gut health. It is essential to study
these proposed health-related bacteria in quercetin metabolism as pure cultures as well as
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in a mixed culture. The abundance of bacteria utilizing quercetin can also vary according
to the dietary conditions. It therefore becomes important to study which bacteria
dominate and how they interact under controlled dietary environments. These studies are
essential as we know the dietary intake of quercetin varies geographically.
Although this study is limited in terms of bioinformatic analysis and predictions
because of limited metadata and number of unequal samples, it gives a foundation for
future research. Experiments highlighting effects of quercetin on gut microbiota in
various dietary conditions can be useful. A study was performed to understand
relationship between quercetin metabolism in the gut, effects on the gut microbiome
structure and dietary intake in healthy elderly Japanese subjects [137]. Studying these
factors can help us understand how the quercetin affects the gut microbiota ecology being
a mediator. Another experiment can be performed where healthy and CRC fecal samples
can be subjected to quercetin and controlled dietary condition to check the metabolic
responses. This study needs further investigation to understand the microbe-microbe
interactions during quercetin metabolism.
This study represents a start to study the subset of gut bacteria which maybe quercetin
degraders and how their abundances vary in the healthy and CRC individuals across
various geographical areas. This study provides a baseline to focus on the gut microbial
role in quercetin degradation and to understand the bacterial community in health and
disease condition which may be useful to understand the effects of quercetin as a
mediator or an effect modifier under various dietary conditions.
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2.5 Conclusion
In this study, we quantified the bacterial patterns of a subset of a total microbiome
which may be capable of degrading quercetin. One of the major factors which may be
driving the bacterial abundances is the diet as we know that the amount of quercetin
consumed varies worldwide. The dietary differences can drive the bacterial interactions
and ecology. Further investigation needs to be done to understand how the bacterial
community of the gut forms and brings about a positive effect from quercetin
transformation.
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